Improving IBD outcomes in the era of many treatment options
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Hepatology
Link
https://www.nature.com/articles/s41575-022-00738-z.pdf
Reference10 articles.
1. D’Haens, G. et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399, 2015–2030 (2022).
2. Ferrante, M. et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399, 2031–2046 (2022).
3. Sandborn, W. J. et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology 162, 1650–1664.e8 (2022).
4. D’Heans, G. et al. OP26 efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J. Crohns Colitis 16 (Suppl. 1), i028–i029 (2022).
5. Danese, S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399, 2113–2128 (2022).
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nano-armor modification of bacteria through supramolecular interactions for disease treatment;Coordination Chemistry Reviews;2024-12
2. Clickable nanozyme enhances precise colonization of probiotics for ameliorating inflammatory bowel disease;Journal of Controlled Release;2024-09
3. Rethinking ustekinumab: An essential reconsideration for moderate-to-severe Crohn's disease;Digestive and Liver Disease;2024-08
4. Monoclonal Antibody Risankizumab for Ulcerative Colitis;JAMA;2024-07-22
5. Analysis of Neuropeptides in the Intestinal Mucus of Patients with Ulcerative Colitis Using RNA Sequencing;Digestion;2024-07-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3